Profusa, Inc. PFSA
Profusa, Inc. (Nasdaq: PFSA) is a cardio-renal-metabolic medical device company. Its next catalyst on record is Lumee Glucose: US FDA approval plan (per 10-K) (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Lumee Glucose — US FDA approval plan (per 10-K) (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Lumee Oxygen | perfusion monitoring in critical limb ischemia | device-combination | NA_NON_THERAPEUTIC |
| Lumee Glucose | continuous glucose monitoring (diabetes) | device-combination | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 15, 2026n/a Profusa issued a senior secured convertible promissory note to Ascent Partners Fund LLC with principal of $769,230.77 for purchase price of $700,000.00.
On October 15, 2026, pursuant to the Purchase Agreement, the Company issued to Ascent a Senior Secured Convertible Promissory Note in the principal amount of $769,230.77, for a purchase price of $700,000.00.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other cardio-renal-metabolic companies
- DexCom, Inc. DXCM
- Penumbra Inc PEN
- Insulet Corp PODD
- MiniMed Group, Inc. MMED
- Heartflow, Inc. HTFL
- iRhythm Holdings, Inc. IRTC
- Pulse Biosciences, Inc. PLSE
- AtriCure, Inc. ATRC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.